The Prognostic Value of Serum Biomarkers in Ewing's Sarcoma

Istituto Ortopedico Rizzoli

Status: Completed

Conditions: Sarcoma, Ewing

Treatments: Other: patients

Study type: Observational

Funder types: Other

Identifiers

NCT05100368

PROSARC

Details and patient eligibility

About

Extraction of laboratory data from blood tests prior to surgical and chemotherapy and other histological, clinical and instrumental data related to the patient's history from the digitized medical Digitized medical records and analysis of the same. The medical records of 1000 patients from January 1, 2000, until December 31, 2020

Enrollment: 1,000 patients

Sex: All

Ages: 2+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with Ewing's Sarcoma and osteosarcoma with established diagnosis;
• Patients with age ≥ 2 years;
• Minimum follow-up duration of 2 years;
• Medical records, complete blood work and instrumental examinations; Regular follow-up.

Exclusion criteria

• Patients with Ewing's sarcoma or osteosarcoma who have received medical treatment (surgery radiotherapy or chemotherapy) in other institutions prior to admission to the Rizzoli Orthopaedic Institute.

Trial design

1,000 participants in 1 patient group

Patients

Description:

Patients with Ewing's Sarcoma and osteosarcoma with established diagnosis

Treatment:

Other: patients